These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 34220701)

  • 1. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wei Q; Xu X; Guo L; Li J; Li L
    Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Zhang S; Qi Z; Wang Y; Song D; Zhu D
    Front Endocrinol (Lausanne); 2023; 14():1203666. PubMed ID: 37465122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Pan R; Zhang Y; Wang R; Xu Y; Ji H; Zhao Y
    PLoS One; 2022; 17(12):e0279889. PubMed ID: 36584211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sodium-glucose co-transporter 2 inhibitors on hepatic parameters: A systematic review and meta-analysis of randomized controlled trials.
    Simental-Mendía M; Sánchez-García A; Rodríguez-Ramírez M; Simental-Mendía LE
    Pharmacol Res; 2021 Jan; 163():105319. PubMed ID: 33246172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials.
    Jin Z; Yuan Y; Zheng C; Liu S; Weng H
    J Diabetes Complications; 2023 Aug; 37(8):108558. PubMed ID: 37499274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Liu X; Chen Y; Liu T; Cai L; Yang X; Mou C
    Front Endocrinol (Lausanne); 2023; 14():1115321. PubMed ID: 36777342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.
    Ng CH; Lin SY; Chin YH; Lee MH; Syn N; Goh XL; Koh JH; Quek J; Hao Tan DJ; Mok SF; Tan E; Dan YY; Chew N; Khoo CM; Siddiqui MS; Muthiah M
    Endocr Pract; 2022 Feb; 28(2):223-230. PubMed ID: 34606980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.
    Arase Y; Shiraishi K; Anzai K; Sato H; Teramura E; Tsuruya K; Hirose S; Deguchi R; Toyoda M; Mine T; Kagawa T
    Clin Drug Investig; 2019 Jul; 39(7):631-641. PubMed ID: 30993553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease.
    Kontana A; Tziomalos K
    World J Gastroenterol; 2019 Jul; 25(28):3664-3668. PubMed ID: 31391764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Liao C; Liang X; Zhang X; Li Y
    PLoS One; 2023; 18(8):e0289616. PubMed ID: 37616255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
    Coelho FDS; Borges-Canha M; von Hafe M; Neves JS; Vale C; Leite AR; Carvalho D; Leite-Moreira A
    Diabetes Metab Res Rev; 2021 Sep; 37(6):e3413. PubMed ID: 33010191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.